IL262746B - A method for treating urothelial cancer in the lower system - Google Patents

A method for treating urothelial cancer in the lower system

Info

Publication number
IL262746B
IL262746B IL262746A IL26274618A IL262746B IL 262746 B IL262746 B IL 262746B IL 262746 A IL262746 A IL 262746A IL 26274618 A IL26274618 A IL 26274618A IL 262746 B IL262746 B IL 262746B
Authority
IL
Israel
Prior art keywords
gemcitabine
individual
antimetabolite
bladder
days
Prior art date
Application number
IL262746A
Other languages
English (en)
Hebrew (he)
Other versions
IL262746A (en
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of IL262746A publication Critical patent/IL262746A/en
Publication of IL262746B publication Critical patent/IL262746B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
IL262746A 2016-05-06 2017-05-05 A method for treating urothelial cancer in the lower system IL262746B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (2)

Publication Number Publication Date
IL262746A IL262746A (en) 2018-12-31
IL262746B true IL262746B (en) 2022-09-01

Family

ID=60203435

Family Applications (2)

Application Number Title Priority Date Filing Date
IL262746A IL262746B (en) 2016-05-06 2017-05-05 A method for treating urothelial cancer in the lower system
IL295592A IL295592A (en) 2016-05-06 2017-05-05 A method for treating urothelial cancer in the lower system

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL295592A IL295592A (en) 2016-05-06 2017-05-05 A method for treating urothelial cancer in the lower system

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP4209221A1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR102435709B1 (enExample)
CN (2) CN118453872A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL262746B (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ787786A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG11201809838VA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
AU2018306299B2 (en) * 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
SG11202003950WA (en) 2017-11-08 2020-05-28 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
JP5913095B2 (ja) 2009-06-26 2016-04-27 タリス バイオメディカル エルエルシー 植込み型薬物送達装置及びその作製方法
EP3884988B1 (en) 2009-12-17 2025-06-18 TARIS Biomedical LLC Implantable device with intravesical tolerability
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
KR20190134832A (ko) * 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SI2890384T1 (sl) * 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
US10137287B2 (en) 2013-03-05 2018-11-27 Taris Biomedical Llc Drug delivery devices and methods for controlled drug release through device orifice
JP6517186B2 (ja) 2013-03-15 2019-05-22 タリス バイオメディカル エルエルシー 薬物透過性構成部材を備えた薬物送達デバイス、及び方法
CA2902556C (en) 2013-03-15 2021-06-22 Heejin Lee Drug delivery devices and methods for drug delivery
CA2919215C (en) 2013-08-19 2022-11-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
JP6856380B2 (ja) 2014-06-26 2021-04-07 タリス バイオメディカル エルエルシー 弾性ポリマー−薬物マトリックス系を含む膀胱内薬物送達デバイス及び方法
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, A PHASE IB, MULTICENTER, OPEN LABEL STUDY EVALUATING SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF GEMRIS 225 MG IN SUBJECTS WITH NON-MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER NCT02720367, 7 June 2017 (2017-06-07) *
ANONYMOUS, A PHASE LB, MULTICENTER, OPEN LABEL STUDY EVALUATING SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF GEMRIS 225 MG IN SUBJECTS WITH MUSCLE-INVASIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER NCT02722538, 7 June 2017 (2017-06-07) *
COCKERILL, P.A. ET AL.,, INTRAVESICAL GEMCITABINE IN COMBINATION WITH MITOMYCIN C AS SALVAGE TREATMENT IN RECURRENT NON-MUSCLE-INVASIVE BLADDER CANCER, 23 May 2015 (2015-05-23) *
LI, J. ET AL.,, EFFECT OF INTERNAL ILIAC ARTERY CHEMOTHERAPY AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR FOR MUSCLE INVASIVE BLADDER CANCER, 31 October 2014 (2014-10-31) *
SHARIAT, S.F. ET AL.,, UPDATE ON INTRAVESICAL AGENTS FOR NON-MUSCLE-INVASIVE BLADDER CANCER, 10 May 2010 (2010-05-10) *
SKINNER, E.C. ET AL.,, SWOG S0353: PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER AND RECURRENCE AFTER 2 PRIOR COURSES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN, 1 October 2013 (2013-10-01) *

Also Published As

Publication number Publication date
AU2017261371A1 (en) 2018-12-13
RU2018142908A (ru) 2020-06-08
WO2017193098A1 (en) 2017-11-09
BR112018072551A2 (pt) 2019-02-19
RS64032B1 (sr) 2023-04-28
EP4209221A1 (en) 2023-07-12
SG11201809838VA (en) 2018-12-28
PT3452053T (pt) 2023-03-03
EP3452053A1 (en) 2019-03-13
HUE060965T2 (hu) 2023-04-28
CN109475571A (zh) 2019-03-15
RU2764747C2 (ru) 2022-01-20
CA3023274A1 (en) 2017-11-09
JP2019514970A (ja) 2019-06-06
MX2018013432A (es) 2019-08-12
RU2022100624A (ru) 2022-02-09
NZ787824A (en) 2025-10-31
KR20220123317A (ko) 2022-09-06
ES2940227T3 (es) 2023-05-04
FI3452053T3 (fi) 2023-04-12
RU2018142908A3 (enExample) 2020-08-31
LT3452053T (lt) 2023-02-10
US20190388338A1 (en) 2019-12-26
JP2024028881A (ja) 2024-03-05
MX2021013461A (es) 2021-12-10
JP7712055B2 (ja) 2025-07-23
KR102435709B1 (ko) 2022-08-25
HRP20221544T1 (hr) 2023-02-17
EP3452053B1 (en) 2022-12-14
EP3452053A4 (en) 2019-12-25
SMT202300047T1 (it) 2023-03-17
SG10201913416PA (en) 2020-03-30
CN118453872A (zh) 2024-08-09
MX389296B (es) 2025-03-20
IL295592A (en) 2022-10-01
KR20190005204A (ko) 2019-01-15
IL262746A (en) 2018-12-31
NZ748252A (en) 2025-10-31
SI3452053T1 (sl) 2023-03-31
PL3452053T3 (pl) 2023-05-08
NZ787786A (en) 2025-10-31
AU2017261371B2 (en) 2023-07-06
JP2022009327A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
Chua et al. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis
IL262746B (en) A method for treating urothelial cancer in the lower system
Zhao et al. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer
Indolfi et al. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma
US12059428B2 (en) Methods of treating tumor metastasis
US12133913B2 (en) Methods of treating overactive bladder using trospium
CN113694009A (zh) 用于使用微针的协同免疫化学治疗的透皮系统及其治疗方法
AU2018366106B2 (en) Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
HK40005970B (en) Method of treating lower tract urothelial cancer
HK40005970A (en) Method of treating lower tract urothelial cancer
KR20250000043A (ko) 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
BR112018072551B1 (pt) Kits para tratamento de câncer de bexiga músculo invasivo
Tremosa et al. NME Digest-July 2016